Traws Pharma sets $5.6M ATM stock capacity under shelf
Traws Pharma, Inc. describes its ability to sell shares of common stock under an existing at-the-market equity offering program.
Rhea-AI Filing Summary
Traws Pharma, Inc. describes its ability to sell shares of common stock under an existing at-the-market equity offering program. Under a new prospectus supplement dated July 10, 2026, the company may offer and sell shares with an aggregate offering price of up to $5,575,709 through Citizens JMP Securities, LLC, reflecting its current “baby shelf” limitation under General Instruction I.B.6 of Form S-3. This activity is conducted pursuant to an at-the-market offering agreement that permits sales of up to $50,000,000 in total and relies on an effective shelf registration statement on Form S-3 declared effective on July 9, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM Agreement Capacity: $50,000,000
Prospectus Supplement ATM Capacity: $5,575,709
Registration Statement Number: 333-297195
+2 more
5 metrics
ATM Agreement Capacity
$50,000,000
Aggregate sales price of common stock permitted under the at-the-market offering agreement with Citizens JMP Securities, LLC
Prospectus Supplement ATM Capacity
$5,575,709
Aggregate offering price of common stock that may be sold under the July 10, 2026 prospectus supplement
Registration Statement Number
333-297195
Form S-3 shelf registration statement covering the ATM sales, declared effective on July 9, 2026
Effective Date of Shelf
July 9, 2026
Date the Form S-3 shelf registration statement was declared effective by the Commission
Prospectus Supplement Date
July 10, 2026
Date of the prospectus supplement governing the current $5,575,709 ATM capacity
Key Terms
At The Market Offering Agreement, shelf registration statement, Prospectus Supplement, baby shelf limitation, +1 more
5 terms
At The Market Offering Agreement financial
"the Company entered into an At The Market Offering Agreement (the “ATM Agreement”)"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement regulatory
"sold pursuant to the Company’s effective shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Prospectus Supplement regulatory
"as supplemented by that prospectus supplement dated July 10, 2026 (the “Prospectus Supplement”)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
baby shelf limitation financial
"which is the Company’s current “baby shelf” limitation under General Instruction I.B.6. of Form S-3"
General Instruction I.B.6. of Form S-3 regulatory
"current “baby shelf” limitation under General Instruction I.B.6. of Form S-3"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock offering did Traws Pharma (TRAW) describe in this Form 8-K?
Traws Pharma detailed its ability to sell shares of common stock under an existing at-the-market equity offering agreement with Citizens JMP Securities, LLC using its Form S-3 shelf registration.
How much stock can Traws Pharma (TRAW) sell under the new prospectus supplement?
Under the July 10, 2026 prospectus supplement, Traws Pharma may sell shares of common stock with an aggregate offering price of up to $5,575,709, subject to its current baby shelf limitation.
What is the total capacity of Traws Pharma’s at-the-market program (TRAW)?
The at-the-market offering agreement with Citizens JMP Securities, LLC allows Traws Pharma to offer and sell common stock with an aggregate sales price of up to $50,000,000, subject to limitations.
Which registration statement covers Traws Pharma’s ATM sales of common stock?
The ATM sales of Traws Pharma’s common stock are covered by its effective shelf registration statement on Form S-3, Registration No. 333-297195, declared effective on July 9, 2026.
Who acts as sales agent for Traws Pharma’s (TRAW) at-the-market offering?
Citizens JMP Securities, LLC acts as sales agent and/or principal for Traws Pharma’s at-the-market offering of common stock under the existing ATM agreement and related prospectus supplement.
What does the “baby shelf” limitation mean for Traws Pharma (TRAW)?
The company states that the $5,575,709 aggregate offering price reflects its current “baby shelf” limitation under General Instruction I.B.6 of Form S-3, constraining how much it can sell at this time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
